Stockscreener 앱 받기
15.90
6.63%
-1.10
전일 마감가:
$17.00
열려 있는:
$16.36
하루 거래량:
577.06K
Relative Volume:
0.45
시가총액:
$1.38B
수익:
$12.59M
순이익/손실:
$-212.39M
주가수익비율:
-5.1535
EPS:
-3.0853
순현금흐름:
$-185.92M
1주 성능:
-3.15%
1개월 성능:
+28.22%
6개월 성능:
+79.36%
1년 성능:
+23.91%
1일 변동 폭
$15.74
$16.80
1주일 범위
$15.36
$17.87
52주 변동 폭
$5.1501
$17.87
이뮤놈 Stock (IMNM) Company Profile
명칭
Immunome Inc
전화
610-321-3700
주소
18702 N. CREEK PARKWAY, BOTHELL
IMNM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
15.90 | 1.48B | 12.59M | -212.39M | -185.92M | -3.0853 |
|
VRTX
Vertex Pharmaceuticals Inc
|
428.08 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
631.04 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
426.73 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.57 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.16 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
이뮤놈 Stock (IMNM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-22 | 개시 | Goldman | Buy |
| 2025-09-05 | 개시 | Craig Hallum | Buy |
| 2025-04-02 | 개시 | Lake Street | Buy |
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-04-30 | 개시 | JP Morgan | Overweight |
| 2024-04-15 | 개시 | Guggenheim | Buy |
| 2024-01-29 | 개시 | Leerink Partners | Outperform |
| 2023-12-19 | 개시 | Wedbush | Outperform |
| 2021-10-29 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
이뮤놈 주식(IMNM)의 최신 뉴스
Can Immunome Inc. stock deliver surprise earnings beatQuarterly Earnings Summary & Intraday High Probability Setup Alerts - newser.com
Immunome (NASDAQ:IMNM) Reaches New 12-Month HighStill a Buy? - MarketBeat
Immunome stock hits 52-week high at 17.34 USD By Investing.com - Investing.com Australia
Immunome stock hits 52-week high at 17.34 USD - Investing.com
Is Immunome Inc. stock a safe haven assetJuly 2025 Opening Moves & Short-Term High Return Ideas - newser.com
Is Immunome Inc. stock bottoming outJuly 2025 Breakouts & High Conviction Trade Alerts - newser.com
Using economic indicators to assess Immunome Inc. potential2025 Technical Patterns & Safe Capital Preservation Plans - newser.com
Historical volatility pattern of Immunome Inc. visualized2025 Stock Rankings & Weekly Watchlist of Top Performers - newser.com
Chart overlay techniques for tracking Immunome Inc.July 2025 Earnings & AI Enhanced Market Trend Forecasts - newser.com
Can machine learning forecast Immunome Inc. recoveryShort Setup & Accurate Buy Signal Alerts - newser.com
Will Immunome Inc. stock reach Wall Street targets2025 Analyst Calls & Low Volatility Stock Suggestions - newser.com
Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference - The AI Journal
What technical signals suggest for Immunome Inc. stock2025 Pullback Review & Short-Term Trading Opportunity Alerts - newser.com
Immunome Bets Big On Cancer Drugs As Shares Outpace The Market - Finimize
Evaluating Immunome Inc. with trendline analysis2025 Historical Comparison & Weekly Setup with High ROI Potential - newser.com
How Immunome Inc. stock benefits from tech adoptionWeekly Investment Recap & Smart Investment Allocation Tips - newser.com
Aug Highlights: How Immunome Inc. stock benefits from tech adoptionMarket Activity Recap & Fast Moving Stock Trade Plans - fcp.pa.gov.br
Immunome (NASDAQ:IMNM) Trading 8.3% HigherTime to Buy? - MarketBeat
Will Immunome Inc. stock outperform Nasdaq indexInsider Selling & Proven Capital Preservation Tips - fcp.pa.gov.br
Can Immunome Inc. stock beat analyst upgradesEarnings Summary Report & Free High Accuracy Swing Entry Alerts - fcp.pa.gov.br
Why Immunome Inc. stock is popular among millennialsLayoff News & AI Driven Stock Price Forecasts - fcp.pa.gov.br
Immunome’s Phase 1 Cancer Study: A Potential Game-Changer? - TipRanks
이뮤놈 (IMNM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
이뮤놈 주식 (IMNM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | Director |
Jun 03 '25 |
Buy |
9.38 |
5,000 |
46,900 |
36,415 |
| Higgins Jack | Chief Scientific Officer |
Mar 27 '25 |
Option Exercise |
1.35 |
5,200 |
7,020 |
18,729 |
| BIENAIME JEAN JACQUES | Director |
Mar 25 '25 |
Buy |
7.78 |
7,800 |
60,684 |
31,415 |
| SIEGALL CLAY B | President and CEO |
Mar 26 '25 |
Buy |
7.29 |
137,100 |
999,459 |
806,736 |
| BIENAIME JEAN JACQUES | Director |
Mar 24 '25 |
Buy |
8.21 |
7,000 |
57,470 |
23,615 |
| Tsai Philip | Chief Technology Officer |
Mar 24 '25 |
Buy |
8.42 |
12,300 |
103,566 |
33,300 |
| SIEGALL CLAY B | President and CEO |
Jan 31 '25 |
Buy |
7.75 |
150,000 |
1,162,500 |
669,636 |
| SIEGALL CLAY B | President and CEO |
Nov 21 '24 |
Buy |
9.54 |
66,057 |
630,263 |
485,693 |
| SIEGALL CLAY B | President and CEO |
Nov 22 '24 |
Buy |
9.78 |
33,943 |
331,918 |
519,636 |
| Lechleider Robert | Chief Medical Officer |
Nov 21 '24 |
Buy |
9.48 |
15,805 |
149,800 |
15,805 |
1.32%
0.35%
자본화:
|
볼륨(24시간):